Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif
Standard
Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif. / Altfeld, Marcus; Livingston, B; Reshamwala, N; Nguyen, P T; Addo, M M; Shea, A; Newman, M; Fikes, J; Sidney, J; Wentworth, P; Chesnut, R; Eldridge, R L; Rosenberg, E S; Robbins, G K; Brander, C; Sax, P E; Boswell, S; Flynn, T; Buchbinder, S; Goulder, P J; Walker, B D; Sette, A; Kalams, S A.
In: J VIROL, Vol. 75, No. 3, 02.2001, p. 1301-11.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif
AU - Altfeld, Marcus
AU - Livingston, B
AU - Reshamwala, N
AU - Nguyen, P T
AU - Addo, M M
AU - Shea, A
AU - Newman, M
AU - Fikes, J
AU - Sidney, J
AU - Wentworth, P
AU - Chesnut, R
AU - Eldridge, R L
AU - Rosenberg, E S
AU - Robbins, G K
AU - Brander, C
AU - Sax, P E
AU - Boswell, S
AU - Flynn, T
AU - Buchbinder, S
AU - Goulder, P J
AU - Walker, B D
AU - Sette, A
AU - Kalams, S A
PY - 2001/2
Y1 - 2001/2
N2 - Virus-specific cytotoxic T-lymphocyte (CTL) responses are critical in the control of human immunodeficiency virus type 1 (HIV-1) infection and will play an important part in therapeutic and prophylactic HIV-1 vaccines. The identification of virus-specific epitopes that are efficiently recognized by CTL is the first step in the development of future vaccines. Here we describe the immunological characterization of a number of novel HIV-1-specific, HLA-A2-restricted CTL epitopes that share a high degree of conservation within HIV-1 and a strong binding to different alleles of the HLA-A2 superfamily. These novel epitopes include the first reported CTL epitope in the Vpr protein. Two of the novel epitopes were immunodominant among the HLA-A2-restricted CTL responses of individuals with acute and chronic HIV-1 infection. The novel CTL epitopes identified here should be included in future vaccines designed to induce HIV-1-specific CTL responses restricted by the HLA-A2 superfamily and will be important to assess in immunogenicity studies in infected persons and in uninfected recipients of candidate HIV-1 vaccines.
AB - Virus-specific cytotoxic T-lymphocyte (CTL) responses are critical in the control of human immunodeficiency virus type 1 (HIV-1) infection and will play an important part in therapeutic and prophylactic HIV-1 vaccines. The identification of virus-specific epitopes that are efficiently recognized by CTL is the first step in the development of future vaccines. Here we describe the immunological characterization of a number of novel HIV-1-specific, HLA-A2-restricted CTL epitopes that share a high degree of conservation within HIV-1 and a strong binding to different alleles of the HLA-A2 superfamily. These novel epitopes include the first reported CTL epitope in the Vpr protein. Two of the novel epitopes were immunodominant among the HLA-A2-restricted CTL responses of individuals with acute and chronic HIV-1 infection. The novel CTL epitopes identified here should be included in future vaccines designed to induce HIV-1-specific CTL responses restricted by the HLA-A2 superfamily and will be important to assess in immunogenicity studies in infected persons and in uninfected recipients of candidate HIV-1 vaccines.
KW - Acquired Immunodeficiency Syndrome/immunology
KW - Binding Sites
KW - Cell Line
KW - Epitopes, T-Lymphocyte
KW - Gene Products, vpr/immunology
KW - HIV-1/immunology
KW - HLA-A2 Antigen/physiology
KW - Humans
KW - T-Lymphocytes, Cytotoxic/immunology
KW - vpr Gene Products, Human Immunodeficiency Virus
U2 - 10.1128/JVI.75.3.1301-1311.2001
DO - 10.1128/JVI.75.3.1301-1311.2001
M3 - SCORING: Journal article
C2 - 11152503
VL - 75
SP - 1301
EP - 1311
JO - J VIROL
JF - J VIROL
SN - 0022-538X
IS - 3
ER -